BIOMARIN PHARMACEUTICAL INC
About BIOMARIN PHARMACEUTICAL INC
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $3.2B
- Net income
- $348.9M
- Total assets
- $7.6B
- Market cap
- $11.0B
- Gross margin
- 77.7%
- Operating margin
- 12.7%
- Net margin
- 10.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $3.2B
- Cost of revenue
- $717.4M
- Gross profit
- $2.5B
- Operating expenses
- $2.1B
- Operating income
- $409.5M
- Income tax
- $133.6M
- Net income
- $348.9M
- EPS (basic)
- $1.82
- EPS (diluted)
- $1.80
Balance sheet
- Total assets
- $7.6B
- Current assets
- $4.0B
- Total liabilities
- $1.5B
- Current liabilities
- $759.0M
- Shareholders’ equity
- $6.1B
Cash flow
- Operating cash flow
- $828.0M
- Investing cash flow
- -$414.2M
- Financing cash flow
- -$42.4M
- Net cash flow
- $371.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $11.0B
- P/E ratio
- 31.4
- EPS (diluted)
- $1.8
- Shares outstanding
- 194.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 23, 1999
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $348.9M in FY2025.
- Revenue grew 74% from FY2021 to FY2025.
- Gross margin of 77.7%, net margin 10.8%.
- Trading 12% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 31.4.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BIOMARIN PHARMACEUTICAL INC.
Write a review
News about BIOMARIN PHARMACEUTICAL INC
News & sentiment via Polygon.io
